Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...